Sulopenem Pharma Grade API is a crystalline beta-lactam active pharmaceutical ingredient supplied in two process presentations: sulopenem etzadroxil for oral tablet, capsule, and granule manufacturing, and a parenteral-grade sulopenem sodium salt for injectable formulations. The oral etzadroxil grade is handled as a moisture-sensitive powder with controlled particle size distribution and residual solvent profile; the injectable grade is processed as a sterile micronized powder or aseptic bulk solution for lyophilization. Product model designation SUL-ETX-102 identifies the oral etzadroxil grade, and SUL-NA-201 identifies the injectable sodium salt for batch record and change-control tracking. These identifiers are internal; they are not pharmacopoeial monograph names. Release is governed by ICH Q7, EU GMP Part II, and 21 CFR 210/211 where applicable to finished drug product manufacturing, with analytical method validation under ICH Q2(R1), impurity qualification under ICH Q3A and ICH Q3B, residual solvents under ICH Q3C, and elemental impurities under ICH Q3D.

Physical characterization of the oral grade includes X-ray powder diffraction for polymorph identity, differential scanning calorimetry for melting and decomposition, and laser diffraction for particle size distribution. The crystalline form of sulopenem etzadroxil is controlled because amorphous content above 5% has been associated with increased hygroscopicity and faster hydrolytic degradation in similar beta-lactam prodrugs. Bulk density is maintained between 0.35 and 0.55 g/cm³ for reproducible capsule filling and tableting. The injectable grade is characterized by particle size D90 ≤20 µm, residual moisture ≤1.5%, and a pH of reconstituted solution between 4.5 and 7.5 at the target concentration. Published data for sulopenem-specific polymorphic transitions are limited; therefore, each batch is released against a reference XRPD pattern generated from the clinical batch.

What Distinguishes Sulopenem from Carbapenem and Penicillin APIs?

Sulopenem is a penem antibiotic, not a carbapenem. The molecule contains a thioethylidene side chain and a C-6 hydroxyethyl group that confer stability against many class A and class C beta-lactamases. In vitro surveillance data show activity against Enterobacterales including Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis, but sulopenem does not cover carbapenemase-producing isolates carrying KPC, NDM, VIM, IMP, or OXA-48-like enzymes. Unlike imipenem, sulopenem does not require cilastatin for renal dehydropeptidase-I inhibition in parenteral formulations. The oral prodrug sulopenem etzadroxil is co-administered with probenecid to inhibit renal organic anion transporter 3 and reduce rapid clearance of the active moiety. This oral bioavailability strategy is different from the beta-lactamase inhibitor combinations used with ceftazidime/avibactam or meropenem/vaborbactam, and it is also different from simple ester prodrugs such as cefuroxime axetil. The oral presentation is evaluated for adults with uncomplicated urinary tract infections caused by susceptible organisms in regions where authorization exists.

Because sulopenem is not yet codified as a monograph in Ph. Eur. or USP, internal release specifications are derived from ICH Q6A and qualified against clinical and stability batches. Oral etzadroxil grade assay is specified at 98.0–102.0% on an anhydrous, solvent-free basis. Total related substances are limited to 1.0%, with any single unspecified impurity ≤0.10%. Residual solvents follow ICH Q3C: methanol ≤3000 ppm, acetone ≤5000 ppm, dichloromethane ≤600 ppm, and isopropyl alcohol ≤5000 ppm where these are used in the final crystallization. Water content is maintained ≤1.0% for the oral grade to minimize hydrolytic beta-lactam ring opening during storage and downstream processing. Elemental impurities are not controlled by legacy heavy-metal limit tests; a documented ICH Q3D risk assessment is required, with particular attention to palladium and nickel if catalytic hydrogenation steps are used. The parenteral grade adds bacterial endotoxin testing per Ph. Eur. 2.6.14 and sterility testing per Ph. Eur. 2.6.1 or USP <71>. Subvisible particulate matter in the reconstituted injectable is controlled per USP <788> method 1: for containers ≤100 mL, acceptance limits are 3000 particles per container at ≥10 µm and 300 particles per container at ≥25 µm.

Moisture Uptake, Residual Solvents, and Tablet Compression Boundaries

Oral sulopenem etzadroxil is not a robust candidate for wet granulation. Beta-lactam hydrolysis accelerates when water activity exceeds the monolayer moisture threshold of the powder blend and when granulation bowl temperatures rise above 40°C. Dry granulation by roller compaction is therefore preferred for tablet and capsule products. Typical roller compaction parameters for moisture-sensitive beta-lactam prodrugs include roll force 4–12 kN/cm, roll speed 2–10 rpm, and screen milling below 1.0 mm; published data for sulopenem etzadroxil itself are limited, and process qualification must be performed on the designated manufacturing line. Blending and compression are performed in suites held at 18–25°C and ≤30% RH. Direct compression is possible when the API particle size distribution is controlled to D90 ≤150 µm and when excipient moisture is ≤1.5%. Tablet hardness should be balanced against disintegration time; compression force above 18 kN on a rotary press has delayed disintegration in comparable high-crystallinity beta-lactam formulations. Capsule filling of the granule uses dosator pins set for a fill-weight variability ≤2.0% RSD. Granule sachet presentation requires a matrix of mannitol and low-moisture binder to prevent caking under 25°C/60% RH accelerated conditions.

The oral etzadroxil prodrug has dissolution-limited absorption, and batch release includes a dissolution specification using compendial apparatus II at 50–75 rpm in a medium selected to discriminate between granule and tablet forms. Bioavailability enhancement by probenecid is part of the dosage form design, not a property of the API alone. Probenecid doses in the fixed combination are typically 500 mg with the etzadroxil component; the product is not interchangeable with injectable sulopenem on a milligram-to-milligram basis because of differences in prodrug conversion, protein binding, and renal handling. The oral tablet is supplied as a film-coated dosage form to mask taste and protect the prodrug from gastric moisture; uncoated tablets are not recommended for clinical release. The granule presentation is not simply a crushed tablet; it is manufactured as a separate dosage form with larger particle size and taste-masking polymer coating. Granules are filled into sachets under low humidity and require a desiccant. Dispersibility testing follows the compendial method for granules; 2 g of granules should disperse in 30 mL of water within 60 seconds at 25°C. Published data for sulopenem-specific granule performance is limited; the dispersion time is a formulation target rather than a regulatory monograph.

Why Are Stability-Indicating Methods Required for both the Prodrug and the Sodium Salt?

The primary degradation routes for sulopenem etzadroxil are hydrolysis of the beta-lactam ring, cleavage of the etzadroxil ester to the active acid, and oxidation of the sulphur atom. HPLC methods therefore separate the prodrug, the active acid, and ring-opened degradation products. For the injectable sodium salt, aqueous hydrolysis follows first-order kinetics at pH values above 7.0 and slows at pH 4.0–5.5; the lyophilized cake is buffered to maintain this range after reconstitution. Forced degradation studies under acidic, alkaline, oxidative, thermal, and photolytic conditions are performed according to ICH Q1A and validated according to ICH Q2(R1). Mass balance is reported as a percentage sum of assay and related substances, with a target of 95.0–105.0%. Degradation products above the identification threshold in ICH Q3B are identified by liquid chromatography-mass spectrometry and qualified in the toxicology programme.

Process validation for sulopenem etzadroxil dry granulation follows a three-batch approach under EU GMP Part II, with sampling across the granulator and tablet press to verify blend uniformity. Blend uniformity acceptance is 90.0–110.0% of label claim with RSD ≤5.0% for low-dose tablets. Content uniformity of the finished tablet follows USP <905> or Ph. Eur. 2.9.40. The manufacturing process is monitored by near-infrared spectroscopy at the tablet press feed frame to detect segregation of the probenecid component. The parenteral aseptic process is validated with media fills at the start of each batch and periodic assessment of lyophilizer shelf temperature mapping; the acceptance criterion for media fills is zero contaminated units in 5000 filled units when the process is run at worst-case constraints.

When the Injectable Salt Is Converted to a Sterile Powder

Injectable sulopenem sodium is handled as a beta-lactam with significant hydrolytic sensitivity in aqueous solution. Terminal sterilization by moist heat is generally avoided because of degradation kinetics; the product is therefore processed by aseptic filtration followed by lyophilization or aseptic powder filling. Aseptic crystallization and micronization are performed in Grade A/ISO 5 zones within Grade B/ISO 7 backgrounds. The freeze-drying cycle maintains product temperature below the collapse temperature of the formulation during primary drying; collapse temperatures for beta-lactam sodium salts are frequently between -25°C and -15°C, but the actual value must be determined by freeze-drying microscopy for each formulation. Residual moisture in the lyophilized cake is controlled ≤1.5% to reduce hydrolytic degradation. Reconstitution time in water for injection at 25°C is formulation-dependent but typically ≤2 minutes for a 1 g presentation. The injectable powder is not suitable for storage in high-humidity environments; once reconstituted, the solution should be used within the validated in-use hold period, usually 4–6 hours at 20–25°C for physicochemical stability. Published data for this specific configuration is limited, and the final concentration and infusion rate must follow the approved product label.

Endotoxin limits for the parenteral grade are derived from the formula K/M, where K = 5 EU/kg body mass and M is the maximum single dose in mg/kg. For a 70 kg adult receiving a 1 g parenteral dose, the calculated limit is 0.35 EU/mg. Injectable-grade release materials are typically tested against a tighter internal limit of 0.15 EU/mg to maintain margin for dilution, multiple containers, and analytical error. The product is incompatible with strong oxidizing agents and should not be co-administered with other beta-lactams through the same intravenous line without compatibility testing. Avoid combination with calcium-containing infusions in the same tubing, as with other beta-lactam sodium salts, because of the risk of particulate calcium carbonate formation under alkaline pH. For injectable use, the sterile sulopenem sodium powder is reconstituted with water for injection to a concentration of 100 mg/mL or 125 mg/mL, then further diluted in sodium chloride 9 mg/mL (0.9%) or dextrose 5% for intravenous infusion over 30–60 minutes. The solution is not compatible with bicarbonate-containing fluids because of alkaline pH.

Release Specification Matrix for Oral and Parenteral Grades

Differences from other beta-lactam APIs extend to regulatory supply. Sulopenem etzadroxil/probenecid is supplied as a fixed-dose combination drug product, not as a standalone API for extemporaneous compounding. The API supplier must declare bovine spongiform encephalopathy/TSE status, nitrosamine risk per EMA CHMP and FDA guidance, and ensure no use of class 1 solvents according to ICH Q3C. The parenteral grade requires a technical agreement covering aseptic processing, depyrogenation of containers, and filter validation per EU GMP Annex 1. These requirements are stricter than for many oral cephalosporin APIs because of the injectable presentation and beta-lactam contamination-control obligations.

The oral grade is packaged in double low-density polyethylene bags inside triple-wall fiber drums under nitrogen overlay. The injectable grade is filled into sterile Type I glass vials sealed with bromobutyl stoppers and aluminum flip-off seals. Hold-time studies are required before assigning retest or shelf-life periods under ICH Q1E; no standard expiry is implied. Transport is controlled at 2–8°C for the injectable grade if stability data show cold-chain requirement, while the oral grade may be shipped at 15–25°C with desiccant protection. The API should not be exposed to ultraviolet light for extended periods; storage in amber glass or opaque containers is used for light protection.